This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Burke, P. J. Articles by Saylor, P. L. Search for Related Content PubMed PubMed Citation Articles by Burke, P. J. Articles by Saylor, P. L.

Drug Induced Host Factors Which Stimulate Growth of Residual Leukemia in Lewis x Brown Norway F₁ (LEW-BN) Rats¹

Cell Proliferation Laboratory, The Johns Hopkins Oncology Center, Baltimore, Maryland 21205

Antitumor synergism occurs with two drugs in sequence when the second drug is given at the time of maximal regrowth of residual leukemia and peak humoral stimulatory activity (HSA). To determine if this enhancement relates to a host derived HSA, studies were conducted in Lewis x brown Norway F₁ rats bearing brown Norway myelocytic leukemia. A significant cure rate was observed in rats treated initially with 1-ß-D-arabinofuranosylcytosine and then given injections of 10⁶ leukemia cells and treated with a second 2-day course of 1-ß-D-arabinofuranosylcytosine in every-8-h s.c. injections in the the 6-day period after the initial drug. No effect on survival of the initial drug or of the second drug given at intervals after day 6 was noted. This result is consistent with the efficacy of treatment at the time of peak HSA and tumor growth. The direct effect of HSA on tumor sensitivity to 1-ß-D-arabinofuranosylcytosine was evaluated by 18-h incubations of leukemia and HSA, followed by bioassay. Increased survival and high cure rates were observed when compared with cultured cells in normal serum. These studies support the notion that host derived factors operative during drug induced aplasia stimulate tumor growth and thereby, if the drugs are properly timed, increase sensitivity to cycle active agents.

¹ Supported by Grant R01 CA 33348 from the National Cancer Institute, NIH, and funds from the Upjohn Company, Kalamazoo, MI.

² To whom requests for reprints should be addressed, at 600 North Wolfe Street, Baltimore, MD 21205.

Received 9/17/85. Revised 12/ 9/85. Accepted 1/ 7/86.